Skip to main content

Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2025.

via HealthDay

WEDNESDAY, April 30, 2025 -- For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless of treatment employed, according to a study published online April 23 in Blood Advances.

Ahmad Y. Abuhelwa, Ph.D., from the University of Sharjah in the United Arab Emirates, and colleagues examined the association of statin use with survival and adverse event outcomes in patients with CLL/SLL initiating contemporary treatment regimens, including ibrutinib, using individual participant data from four randomized trials.

Overall, 29 percent of 1,467 patients were using statins. The researchers found a significant association for statin use with improved overall survival, progression-free survival, and cancer-specific survival (adjusted hazard ratios, 0.55, 0.73, and 0.39, respectively). The findings were consistent for those treated with ibrutinib and nonibrutinib and for CLL versus SLL diagnosis. There was no significant association observed between statin use and grade ≥3 adverse effects.

"These findings don't allow us to say for certain that statins directly improve cancer outcomes," Abuhelwa said in a statement. "However, the fact that this association remained strong even after accounting for multiple factors makes it an important area for future research."

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Leukemia Stem Cell-Based Method Aids Relapse Prediction in Acute Myeloid Leukemia

FRIDAY, Aug. 29, 2025 -- An assay that uses leukemia stem cells (LSCs) to assess measurable residual disease (MRD) outperforms traditional methods in patients with acute myeloid...

Mortality Up for Children With Leukemia From Lowest SES Neighborhoods

THURSDAY, Aug. 28, 2025 -- Children with acute lymphoblastic leukemia (ALL) from the lowest socioeconomic status (SES) neighborhoods have an increased risk for mortality...

Patients With Leukemia Have Higher Infection Risk During Immunoglobulin Replacement Therapy

THURSDAY, Aug. 7, 2025 -- For patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy (IgRT) is associated with an increased...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.